Icahn on Genzyme manufacturing; Rid Pharma preps for trial in Bangladesh;

> Carl Icahn tells Forbes about the thinking leading up to his pre-Sanofi-acquisition play for Genzyme: "How broken is manufacturing? Could the FDA be so angry it would handicap Genzyme for years to come?" Article

> A drug court has outlined charges against five owners and officers of Rid Pharmaceuticals, accused of manufacturing adulterated paracetamol syrup linked to the deaths of 28 children in 2009. Story 

> Although pharmaceutical products are a "good little business," British chemical maker Yule Catto is open to selling its drug ingredient division. Article

> A wealthy Russian businessman and the Belarusian Belbiopharm group may join forces for the construction of an import-curbing pharma plant in Belarus. Story

> GSK has invested $4 million in a new plant in Sri Lanka to produce the OTC painkiller Panadol. Story

> While attempting to repair electrical service following a snow-induced roof collapse at First Boston Pharma, workers knocked a ladder into an electrical cabinet, sparking an explosion that started a fire. Story

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.